tirzepatide early glucose reduction
Early glycemic response: Tirzepatide’s rapid onset compared to Semaglutide in type 2 diabetes - comparison
Semaglutide and tirzepatide are both GLP-1-based injectables, but tirzepatide’s dual-agonist profile gives it a distinct edge for obesity treatment. While semaglutide was the first GLP-1 approved for weight loss, tirzepatide’s recent FDA clearance expands the therapeutic toolbox for patients struggling with excess weight. Both drugs lower appetite, improve